ADC Therapeutics SA (ADCT) Misses Q4 EPS by 51c

ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.97), $0.51 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $16.79 million versus the consensus estimate of $15.32 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'